34 Biostatistics & Statistical Programming CROs

What is biostatistics and statistical programming, and when do you need it?

Biostatistics is the discipline that decides, before a single patient is dosed, how a trial will be judged a success or a failure, and statistical programming is the machinery that produces the actual numbers from the collected data. The two travel together. A biostatistician owns the design choices: the primary and key secondary endpoints, the sample size and power calculation, the randomization scheme, the analysis populations (ITT, per-protocol, safety), how missing data will be handled, and the multiplicity strategy when you are testing several hypotheses. The statistical programmer takes the locked database and builds the CDISC datasets and the tables, listings, and figures (TLFs) that go into the clinical study report and the submission.

You need this function earlier than most first-time sponsors expect. The statistical analysis plan (SAP) and the sample size sit inside protocol design, not after data collection, because the trial has to be sized and randomized correctly from the start or the result is not defensible later. A trial that enrolls before the SAP is finalized is borrowing against its own credibility. In practice the biostatistics group is engaged at protocol writing, stays involved through randomization and any interim analyses, and then carries the bulk of the work in the window between database lock and topline results, where the programming of TLFs and the analysis itself become the critical path to your readout.

The work spans every phase and every modality. A Phase 1 dose-escalation needs a model-based or rule-based design and the stats to support dose decisions; a Phase 2 needs interim looks and often an adaptive element; a pivotal Phase 3 needs a locked SAP, a Data Safety Monitoring Board (DSMB or IDMC) charter and unblinded interim analyses, and, when you reach filing, integrated summaries of safety and efficacy (ISS and ISE) pooled across studies. Oncology, rare disease, and gene and cell therapy each bend the design in different directions (time-to-event endpoints, small-N and external controls, long-term follow-up), which is exactly why matching the statistical team to your indication matters.

What does a biostatistics and statistical programming CRO actually do?

Most sponsors outsource this either as part of a full-service CRO package or, very commonly, as a standalone functional service provider (FSP) engagement, because biostatistics and statistical programming are clean to carve out and run with a dedicated vendor. The deliverables are concrete and inspectable, which makes them easier to compare across vendors than softer services. Here is what the work actually covers.

• Statistical analysis plan (SAP): the document that pre-specifies endpoints, analysis populations, statistical methods, handling of missing data and dropouts, and the estimand, finalized and signed before unblinding.
• Sample size and power: the calculation that justifies your N, with the assumptions (effect size, variability, dropout, alpha and power) stated so a reviewer and a DSMB can check them.
• Randomization and IRT/RTSM specification: generating randomization schedules (stratified, block, or adaptive) and the stratification factors, and supporting the interactive randomization system.
• CDISC programming: SDTM datasets from collected data and ADaM analysis datasets, plus define.xml and the reviewer's guides, built to the standards the FDA and PMDA expect for submission.
• Tables, listings, and figures (TLFs): the SAS or increasingly R programs that produce every efficacy and safety output in the clinical study report, double-programmed and validated.
• Interim analyses and DSMB/IDMC support: unblinded interim looks, group-sequential or adaptive boundaries, and the closed and open reports that go to an independent monitoring committee.
• Integrated summaries (ISS/ISE): pooling safety and efficacy across multiple studies for the NDA or BLA, one of the heaviest programming efforts in a submission.
• PK/PD and exposure-response, statistical input to the clinical study report (ICH E3), and responses to regulatory questions during review.

How do you choose a biostatistics and statistical programming CRO?

Start with fit to your study type and indication, not the headline hourly rate. A group that is excellent at large oncology survival analyses may be the wrong choice for a small rare-disease trial that leans on Bayesian methods or an external control arm, and an adaptive Phase 2 needs a team that has actually run group-sequential or adaptive designs before, not one reading about them on your dollar. Ask for the lead biostatistician's experience in your therapeutic area and your specific endpoint type (time-to-event, responder, repeated-measures), and confirm the named statistician and lead programmer, not just the company logo, will be the people on your study.

The second filter is CDISC and submission track record, because this is where weak vendors quietly create six-figure remediation later. Confirm SDTM and ADaM are delivered conformant from the start, with define.xml and reviewer guides, and ask how many of their packages have actually cleared an FDA or PMDA submission. The third is process and validation discipline: double programming of key outputs, version-controlled programs, a documented validation trail, and an SOP set you can audit. Run the practical checklist below against two or three vendors scored on the same written scope.

• Quality and GxP status: GCP-compliant quality system, validated computing environment (21 CFR Part 11), documented validation and double-programming SOPs, and audit and inspection history you can review.
• Capacity and lead time: real availability of senior statisticians and programmers in your window, and honest turnaround on the SAP, dry-run TLFs, and database-lock-to-topline timeline, since this work usually sits on the critical path.
• Modality and indication fit: demonstrated experience with your study type and endpoints (oncology time-to-event, rare-disease small-N, adaptive or Bayesian designs, gene and cell therapy long-term follow-up), not a generalist resume.
• Region and regulatory track record: packages that have cleared the agencies you are filing with (FDA, EMA, PMDA, NMPA), and familiarity with the relevant ICH guidance (E9 and the E9(R1) estimand addendum, E3, E6 GCP).
• Data quality and standards: CDISC SDTM and ADaM delivered conformant by default, define.xml and reviewer guides included, and clean handoff with your data management vendor and EDC.
• IP and confidentiality: clear ownership of programs, datasets, and outputs, blinded-team firewalls for interim analyses, and confidentiality terms that hold for an unblinded statistician supporting a DSMB.